(Pi) Patient interaction® Introduces New Tool to Better Target Patient Recruitment Efforts for Clinical Trials
(Pi) Patient interaction®, the clinical trial experts at First Marketing, today announced the introduction of a new profiling tool called Precision Patient Insights.
POMPANO BEACH, Fla., June 16, 2005 - (Pi) Patient interaction, the clinical trial experts at First Marketing, today announced the introduction of a new profiling tool called Precision Patient Insights. (Pi) utilizes this proprietary process, as well as experience in therapeutic areas across all phases of studies - from phase I to phase IV and beyond - to help clinical trial sponsors learn as much as they can about patients with a specific therapeutic condition. These targets represent the most likely prospects for enrollment in a specific clinical trial.
"Precision Patient Insights uses more than just geographic and demographic information," explains First Marketing's president Ron Drenning. "It blends lifestyle and behavior patterns - known as psychographics - to better understand what motivates this specific group of individuals. Through additional overlays, Precision Patient Insights also enhances the patient profile with media preferences for print, radio and broadcast, allowing for better targeting of the patient recruitment media campaign."
The goal is to provide clinical trial sponsors with predictive information based on an analysis of individuals who have self-reported having a given therapeutic condition. Details include socioeconomic/behavioral characteristics such as income, age, occupation, neighborhood surroundings, household composition and lifestyle habits. Precision Patient Insights also links to a large network of consumer research on media behaviors, such as newspaper, radio and television usage. The result is a unique glimpse into the daily lives of the prospective patient.
"The profile creates a more complete picture of the patient recruitment target," adds Drenning. "Our strategic team can then prepare recruitment materials such as posters, brochures and ads that reinforce themes, images and messages that truly motivate response. Likewise, this profile can be applied to patient retention materials that promote compliance. Better targeting means better results, increasing the likelihood that a clinical trial will enroll on time and bring a product to market more quickly and with less expense."
(Pi) will be exhibiting at the Drug Information Association (DIA) 41st Annual Meeting in Washington, D.C., from June 26-30 at booth 1041.
About the Company
(Pi) Patient interaction, the clinical trial experts at First Marketing, have more than 20 years of experience in patient recruitment and retention. Through a full-service approach, they help facilitate, accelerate and enhance the study enrollment and retention process. Services include site analysis, selection and optimization; online ordering system for recruitment and retention materials; informed consent tools; patient-focused market research; and targeted patient recruitment and retention campaigns. First Marketing helps clients from a variety of industries, including healthcare, financial, telecom and travel, maximize customer relationships through education, cross-sell/upsell, loyalty rewards and channel marketing solutions.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
